Directorate Changes
22/12/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231222:nRSV6722Xa&default-theme=true
RNS Number : 6722X Evgen Pharma PLC 22 December 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Directorate Changes
· Appointment of Toni Hänninen as Permanent CFO and Board Director
· Retirement of Susan Clement-Davies as Board Member
Alderley Park, UK - 22 December 2023: Evgen Pharma plc (AIM: EVG), a clinical
stage drug development company developing sulforaphane-based medicines,
announces that Toni Hänninen has been appointed as permanent Chief Financial
Officer (CFO) and he will join the Board of Directors as a Director. The
Company also announces that Non-Executive Director, Susan Clement-Davies, will
be retiring from the Board.
Toni Hänninen
Toni Hänninen was appointed interim CFO in September 2023. He is now taking
on the CFO role on a permanent basis and moving onto the Board as a
Director. His appointment is effective from 1 January 2024.
Toni was previously CFO at Faron Pharmaceuticals Ltd, an AIM and Nasdaq First
North listed clinical stage biopharmaceutical company based in the Finland and
the US, developing novel treatments for medical conditions with significant
unmet needs. He holds over 20 years of experience in business development and
senior finance roles in both public and private companies, working in mature
and emerging markets particularly in Europe and the USA where he has
accomplished successful fundraises, transactions and fiscal management in the
sector. Toni has an MBA from the Helsinki School of Economics (now Aalto
University).
Retiring board member
Evgen Pharma also confirms that Susan Clement-Davies is retiring from her
position as Non-Executive Director on the 31 December 2023 in order to focus
on her other board positions. Susan has been on the Evgen Pharma board since
2018 and has provided valuable insight and expertise in that time.
Dr Susan Foden, Non-Executive Chair of Evgen Pharma said:
"I am very pleased to welcome Toni in as permanent CFO and I look forward to
working with him on the board. Toni's broad company experience is already
making a difference to Evgen and he is providing considerable support to the
rest of the executive team in driving projects forward.
"On behalf of the Board, I also want to thank Susan for her significant
contributions to the Board and the company for the past five years and wish
her well for the future."
Toni Hänninen, CFO of Evgen said:
"I'm delighted to join the Evgen executive team and Board as permanent CFO and
Executive Director. I've thoroughly enjoyed working with Huw, Helen and the
rest of the team so far, and look forward to helping build value for
shareholders."
Huw Jones, CEO of Evgen said:
"Toni's considerable skill set is highly complementary to the rest of our
talented team and it's great to be working with him. Welcome to the team on a
permanent basis Toni.
As we reported in the half year results in October, we have made substantial
progress against strategic goals, despite the toughness of the market
environment. We continue to be well positioned to commercialise the potential
of SFX-01 both through our own studies and through a range of collaborations.
We are looking forward to a busy 2024."
-Ends-
Enquiries:
Evgen Pharma plc +44 1625 466591 (tel:%204401625466591)
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish (Nominated Advisor and Broker) +44 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
Instinctif Partners +44 207 457 2020
evgen@instinctif.com
Melanie Toyne-Sewell / Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing
sulforaphane based medicines for the treatment of multiple diseases. The
Company's core technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane and novel
proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b
study of the Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be
investigated initially in this indication as an investigator sponsored study
in the Netherlands supported by a substantial non-dilutive grant.
The Company also has a wide number of collaborations with leading academic
centres in the UK, Europe and the US as part of the continuing strategy to
build the scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum disorder. The
deal, if successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com (http://www.evgen.com)
.
INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM
RULES FOR COMPANIES ("AIM RULES")
Full name: Toni Markus Antero Hanninen
Age: 46
Current directorships or partnerships: Historic directorships and partnerships in previous 5 years
Borealito GmbH
There is no further information to be disclosed in relation to the appointment
pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAEFLFLXLLBFBK